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Background: Lactate dehydrogenase A (LDHA) and Pyruvate Kinase M2 (PKM2) are important enzymes of
glycolysis. Both of them can be phosphorylated and therefore regulated by Fibroblast growth factor receptor 1
(FGFR1). While phosphorylation of LDHA at tyrosine10 leads to tetramerization and activation, phosphorylation of
PKM2 at tyrosine105 promotes dimerization and inactivation. Dimeric PKM2 is found in the nucleus and regulates
gene transcription. Up-regulation and phosphorylation of LDHA and PKM2 contribute to faster proliferation under
hypoxic conditions and promote the Warburg effect.
Methods: Using western blot and SYBR Green Real time PCR we investigated 77 thyroid tissues including 19 goiter
tissues, 11 follicular adenomas, 16 follicular carcinomas, 15 papillary thyroid carcinomas, and 16 undifferentiated
thyroid carcinomas for total expression of PKM2, LDHA and FGFR1. Additionally, phosphorylation status of PKM2
and LDHA was analysed. Inhibition of FGFR was performed on FTC133 cells with SU-5402 and Dovitinib.
Results: All examined thyroid cancer subtypes overexpressed PKM2 as compared to goiter. LDHA was
overexpressed in follicular and papillary thyroid cancer as compared to goiter. Elevated phosphorylation of
LDHA and PKM2 was detectable in all analysed cancer subtypes. The highest relative phosphorylation levels of
PKM2 and LDHA compared to overall expression were found in undifferentiated thyroid cancer. Inhibition of
FGFR led to significantly decreased phosphorylation levels of PKM2 and LDHA.
Conclusions: Our data shows that overexpression and increased phosphorylation of PKM2 and LHDA is a common
finding in thyroid malignancies. Phospho-PKM2 and Phospho-LDHA could be valuable tumour markers for thyroglobulin
negative thyroid cancer.
Keywords: Pyruvate Kinase M2, Lactate dehydrogenase A, Fibroblast growth factor receptor 1, Warburg effect, Thyroid,
Tumour markerBackground
The Warburg effect describes a general feature of cancer
cells to show elevated glucose uptake and lactate pro-
duction even in the presence of oxygen [1]. Warburg
proposed an impaired glucose oxidation, which leads to
extensive excretion of lactate under normoxia [2]. How-
ever, recent data showed that the Warburg effect is* Correspondence: pkachel@ukaachen.de
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unless otherwise stated.common not only in cancer cells but also in induced
pluripotent stem cells [3] and in proliferating T cells [4].
These findings raise many questions related to cancer
specific alterations in glycolysis and their possible use as
prognostic or therapeutic targets.
Pyruvate Kinase (PK), catalysing the step from phos-
phoenolpyruvate to pyruvate, is a key enzyme of glycoly-
sis. Furthermore it is an important regulator of the
Warburg effect. In thyroid tissue there are two isoen-
zymes: pyruvate kinase M1 (PKM1) and pyruvate kinase
M2 (PKM2), which result from alternative splicing ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Antibodies
Antibody Company
PKM2 Antibody Cell Signaling Technology,
Cambridge, England
Phospho-PKM2 (Tyr105) Antibody Cell Signaling Technology,
Cambridge, England






FGF Receptor 1 (D8E4) Cell Signaling Technology,
Cambridge, England
Monoclonal Anti-ß-Aktin Clone AC15 Sigma Aldrich, Saint Louis, USA
Goat anti Rabbit IgG HRP Santa Cruz Biotechnology, Santa
Cruz, USA
Goat anti Mouse IgG HRP Santa Cruz Biotechnology, Santa
Cruz, USA
PKM1 Rabbit Polyclonal Ab Signalway Antibody, Maryland,
USA
Specific primary and secondary antibodies used for western blot analysis.
Table 2 Specific primer
Targetgene Sense Antisense
PK-M1/2 5′CTG GGA AGC CTG
TCA TCT GT-3′
5′- AGT CCC CTT TGG
CTG TTT CT-3′
LDHA 5′-GGC CTC TGC CAT
CAG TAT CT-3′
5′-GCC GTG ATA ATG
ACC AGC TT-3′
FGFR1 5′-ACA CTG CGC TGG
TTG AAA A- 3′
5′-TGG TAT GTG TGG
TTG ATG CTC- 3′
yWHAZ
(Housekeeping)
5′-AGC AGG CTC AGC GAT
ATG AT-3′




5′-ACC CAG AAG ACT
GTG GAT GG-3′
5′-TTC TAG ACG GCA
GGT CAG GT-3′
Specific primers for target genes and housekeeping genes used for SYBR
Green Q-RT-PCR.
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the dominant isoenzyme in all examined benign and malig-
nant thyroid tissues [6] (Additional file 1). Higher levels of
PKM2 in tumour tissues contribute to growth advantage
and faster progression in xenograft models as compared to
cancer cells expressing PKM1 [7]. However, elevated levels
of inactivated dimeric PKM2 are found in cancer cells [8].
This inactivation may be promoted by different mecha-
nisms [9,10] and suggests that PKM2 may possess other,
non-glycolytic functions such as regulation of transcrip-
tion. In addition to these effects involvement of other pro-
teins, which may dramatically affect the function of PKM2,
has been reported [10,11]. It has been demonstrated that
phosphorylation of tyrosine 105 of PMK2 by fibroblast
growth factor receptor 1 (FGFR1) prevents tetramerization
and inactivates PKM2. As a consequence this leads to
faster proliferation under hypoxic conditions and in-
creased tumour growth in xenograft models [12]. The
enzymatically inactivated dimeric form of PKM2 can
be translocated to the nucleus and may act as a pro-
tein kinase regulating gene transcription implicated in
tumour growth [13-16]. Inactivation of PKM2 leads to
accumulation of upstream glycolytic metabolites and
activation of the pentose-phosphate pathway, hexosamine-
pathway and serine biosynthesis. This results in increased
availability of metabolites for redox control and nucleotide
biosynthesis [11,17]. With regard to clinical employment
as a tumourmarker, a great diagnostic and prognostic po-
tential of PKM2 has been demonstrated for several malig-
nancies including oesophagus, pancreas or colorectal
cancer [18,19]. However, data concerning PKM2 in thyroid
cancer is still lacking.
Lactate dehydrogenase (LDH) catalyses the conversion
from pyruvate to lactate. Active LDH consists of four
monomers. The two different monomers lactate de-
hydrogenase A (LDHA) and lactate dehydrogenase B
(LDHB) are expressed in an organ depending manner.
While LDHA preferentially turns pyruvate into lactate,
LDHB works the opposite way [20].
LDHA is up-regulated in a wide range of tumour tis-
sues including lung, breast, endometrium, urinary blad-
der, testicular germ cell and large intestine cancers
[20,21]. Down-regulation or inhibition of LDHA resulted
in decreased ATP levels, reduced mitochondrial mem-
brane potential and an increase in oxidative stress that is
linked to cell death. Furthermore, decreased levels of
LDHA were related to inhibition of tumour xenograft
maintenance and progression [22,23]. Investigations on
thyroid tissues showed a decreased LDHA/LDHB ratio
in thyroid oncocytoma and follicular tumours compared
to normal thyroid tissue which was altered by estrogen
related receptor alpha. Those tumours were more
dependent on oxidative phosphorylation [24]. In contrast
to PKM2, FGFR1-mediated phosphorylation of LDHA attyrosine 10 (y10) promotes tetramerization and turns
LDHA into the active enzyme [25].
Fibroblast growth factor receptors (FGFR) play an im-
portant role in many human malignancies, such as blad-
der or breast cancer [26,27]. They are involved in the
regulation of cellular proliferation, differentiation, migra-
tion and cell survival [28]. With regard to thyroid tissue,
the most studied receptor of this family, FGFR1, is over-
expressed in differentiated thyroid cancer and in thyroid
hyperplasia [29,30].
So far, FGFR1-mediated phosphorylation effects on
LDHA and PKM2 have only been demonstrated in cell
culture experiments without any relevance to human
cancer tissue, especially thyroid carcinoma.
In this study we investigated the expression of PKM2,
LDHA and FGFR1 in thyroid benign and malignant tissues
by employment of qPCR and western blot. Additionally, a
possible impact of FGFR1-mediated phosphorylation of
PKM2 and LDHA on thyroid malignancy was evaluated.
Figure 1 Protein analysis of PKM2, LDHA and FGFR1 expression in thyroid tissues. Representative images of western blot performed with
total protein lysates obtained from thyroid tissues and antibodies against total-PKM2, Phospho-PKM2, total-LDHA, Phospho-LDHA and FGFR1.
Thyroid samples were divided into following histological subgroups: benign goiter (Goiter), follicular adenoma (FA), follicular thyroid cancer (FTC),
papillary thyroid cancer (PTC) and undifferentiated thyroid cancer (UTC). ß-actin was used as a normalizing marker.
Kachel et al. BMC Cancer  (2015) 15:140 Page 3 of 13Methods
Tissue
A total of 77 thyroid tissue samples, including 19 goi-
ter tissues, 11 follicular adenomas (FA), 16 follicular
carcinomas (FTC), 15 papillary thyroid carcinomas
(PTC) and 16 undifferentiated thyroid carcinomas(UTC) were collected from patients at the surgical
institute of the Martin Luther University Halle Wittenberg.
The study was approved by the ethical committee
of the medical department of the Martin Luther Uni-
versity Halle Wittenberg. All patients gave written
consent.
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Frozen tissue samples were collected directly after
surgery and stored in liquid nitrogen. Tissue specimens
were divided and sections where prepared and stained
with hematoxylin and eosin to confirm the pathological
diagnosis. After confirmation frozen tissue specimens
were homogenised and further divided for RNA- or
protein extraction. For protein extraction the homogen-
ate was lysed using a protein lysis buffer (7 M urea,
2 M thiourea, 4% Chaps, 40 mM DTT). Protein con-
centration was measured by using the Bradford assay
method. Proteins were separated by SDS-PAGE blotted
on PVDF membrane and blocked with 5% BSA for one
hour. They were incubated overnight in a 1:1000 dilu-
tion of the primary antibody. β-actin was used as nor-
malizing marker. Total lysate from cell line FTC133
was used as positive control. FTC133 is a thyroid can-
cer cell line, which was obtained from a lymph node
metastases from a 42-year-old male with follicular thy-
roid cancer. As proven in preliminary experimentsFigure 2 Evaluation of total- and Phospho-PKM2 protein expression.
PTC and UTC were analysed by employment of western blot analysis and e
was measured in relation to FTC133 as positive control and then normalize
expressed as percent to positive control defined as 100%. *p < 0.05 indicateFTC133 expresses PKM1, PKM2, LDHA and FGFR1 on
mRNA and protein levels (Additional file 2). Mem-
branes were first stained with Phospho-PKM2 or
Phospho-LDHA antibody, respectively. Subsequently,
they were treated with stripping buffer (15 g glycin, 1 g
SDS, 10 ml Tween adjusted to pH 2.2 and filled up
with H2O to 1 l) and tested for remaining signals. They
were again incubated overnight with total LDHA or
PKM2 antibody, respectively. Protein expression was
measured in relation to FTC133 as positive control and
then normalized to the expression of ß-actin as a nor-
malizing marker. Differences are expressed in percent
to positive control defined as 100%. In order to evaluate
the expression and phosphorylation status of PKM2
and LDHA we subjected total protein lysates to western
blot with specific antibodies raised against total PKM2
and LDHA, phosphorylated y105 of PKM2 and phos-
phorylated y10 od LDHA. To evaluate the expression
of FGFR1 antibodies against total FGFR1 were used
(Table 1).Total and y105-phosphorylated PKM2 expressions in goiter, FA, FTC,
valuated densitometrically with ImageJ software. Protein expression
d to the expression of ß-actin as normalizing marker. Differences are
s a statistical significance.
Figure 3 Phospho-PKM2/total PKM2 ratio. Total and y105-phosphorylated PKM2 expression in goiter, FA, FTC, PTC and UTC were analysed by
employment of western blot (see Figure 1). Phospho-PKM2/total-PKM2 ratio was built to show phospho-PKM2 in relation to total-PKM2. *p < 0.05
indicates a statistical significance.
Figure 4 Correlations between Phospho-PKM2/total-PKM2. Correlation between ratio of Phospho-PKM2/total-PKM2 and FGFR1 expression.
Pearson correlation was applied.
Kachel et al. BMC Cancer  (2015) 15:140 Page 5 of 13
Figure 5 Correlations between Phospho-LDHA/total-LDHA and FGFR1 expression. Correlation between ratio of LDHA/total-LDHA and
FGFR1 expression. Pearson correlation was applied.
Figure 6 mRNA expression of Pyruvate Kinase M1 and M2 (PKM1/2). Expression of PKM1/2 in goiter, FA, FTC, PTC and UTC was analysed by
employment of Q-RT-PCR. mRNA expression was measured in relation to FTC133 as positive control and then normalized to the expression of
yWHAZ and GAPDH as normalizing markers. Differences are expressed as percent to positive control defined as 100%. *p < 0.05 indicates a
statistical significance.
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The transcripts of FGFR1, PKM and LDHA were investi-
gated by employment of quantitative RT-PCR and primer
pairs listed in Table 2. 1 μg of total RNA was reversely
transcribed by using SuperScript II Kit according to the
manufacturer’s instructions (Invitrogen). qPCR was con-
ducted with Rotor Gene SYBR Green PCR Kit (Qiagen) on
Rotor Gene Q® Qiagen 2 plax Platform (Qiagen). The
cycling conditions were as follows: PCR initial activa-
tion step for 5 min. at 95°C, 40 cycles of two step cyc-
ling which included denaturation for 5 sec at 95°C and
10 sec of combined annealing and extension at the in-
dividual primer temperature between 57°C and 62.5°C.
Relative mRNA levels of the transcripts were mea-
sured in relation to FTC133 as positive control and
then normalized to the expression of the housekeeping
genes YWHAZ and GAPDH. Differences are expressed
in percent in relation to positive control defined as
100%.Figure 7 Evaluation of total- and Phospho-LDHA protein expression.
and UTC were analysed by employment of western blot analysis and evalu
measured in relation to FTC133 as positive control and then normalized to
expressed as percent to positive control defined as 100%. *p < 0.05 indicateCell culture experiments
8505C and FTC133 cells were grown in DMEM/F12 supp-
plemented with 10% FCS and 1% PenStrep and incubated
at 37°C, 5% CO2. For B-CPAP RPMI 1640 medium was
used. FGFR1 inhibition experiments were performed on
FTC133 cells by employment of Receptor Tyrosine Kinase
Inhibitors TKI-258 (Dovitinib, Biomol) and SU-5402
(Sigma-Aldrich). Inhibition was conducted over 4 h with
the indicated inhibitor concentrations. Control cells re-
ceived corresponding concentrations of DMSO.Statistical analysis
Statistical analyses were performed with IBM SPSS (ver-
sion 20) software by employment of a priori test. In case
of p < 0.05 a Kruskal Wallice and Mann Whitney U test
for subgroup analysis was performed. For correlation
analysis the Pearson coefficient was used. Boxplots were
performed according to Tukey’s definition.Total and y10-phosphorylated LDHA expressions in goiter, FA, FTC, PTC
ated densitometrically with ImageJ software. Protein expression was
the expression of ß-actin as normalizing marker. Differences are
s a statistical significance.
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Expression and phosphorylation of y105 of pyruvate
kinase M2 (PKM2)
As demonstrated in Figures 1, 2 and 3, the protein levels of
total and phosphorylated PKM2 were expressed noticeably
higher in every cancer subgroup as compared to goiter or
FA. The highest and significant expression of total- and
Phospho-PKM2 was found in UTC as compared to goiter
or FA samples. A similar and significantly elevated expres-
sion pattern of both PKM2 proteins was also found in
other cancer groups. Comparisons between carcinoma tis-
sues and FA revealed a noticeably increased expression of
total- and Phospho-PKM2 in FTC, PTC and UTC. How-
ever, only the difference between UTC and FA was found
significant. Analysis of the median expression of total
PKM2 in each histological subgroup revealed the following
percentages of expressional values: 26.6% (goiter), 39.3%
(FA), 80.5% (FTC), 74.1 % (PTC) and 89.7% (UTC). Me-
dian levels of Phospho-PKM2 in each histological sub-
group showed 6.4% (goiter), 14.38% (FA), 58.8% (FTC),
59.2% (PTC) and 85% (UTC). The difference between the
median of total PKM2 expression (89.7 %) and Phospho-
PKM2 levels (85%) was just 4,7% for UTC. This cancer
subtype demonstrated the highest relative PKM2 phos-
phorylation. Phospho-PKM2/total-PKM2 ratio showedFigure 8 Phospho-LDHA / total-LDHA ratio. Total and y10-phosphorylat
employment of western blot (see Figure 1). Phospho-PKM2 / total-PKM2 ra
*p < 0.05 indicates a statistical significance.significantly increased relative phosphorylation in all
cancer subgroups compared to goiter and FA (Figure 3).
In further analysis, Phospho-PKM2 revealed a significant
correlation with FGFR1 expression (r 0.39, p < 0.05) (data
not shown). To minimize the confounding factor of in-
creasing PKM2 expression from benign to malignant
tissue, a ratio between phosphorylated and total PKM2
expression (Phospho-PKM2/PKM2) was used. This ratio
showed an even higher correlation of r 0.439 (p < 0.05) with
FGFR1 expression (Figure 4) and also higher as Phospho
LDHA/LDHA ratio (Figure 5). FGFR1 and Phospho-
PKM2/PKM2 showed a significant correlation of r 0.529,
(p < 0.05) in the group of UTC (data not shown).
Unfortunately, designing a qPCR primer for analysis
including every transcript variant of PKM2 separately
without amplification of PKM1 was not possible. This
problem was approached by using the primers to amplify
PKM1 and PKM2 simultaneously. According to previous
studies, PKM1 levels in thyroid tissue are very low as
compared to PKM2 [6] (Additional file 1). In this
study the focus was on combined PKM1/2 mRNA
analysis, which still provided enough information
about PKM2 expression. As shown in Figure 6, ana-
lysis of mRNA levels revealed significantly higher ex-
pression of PKM1/2 in UTC as compared to goiter, FAed LDHA expression in goiter, FA, FTC, PTC and UTC were analysed by
tio was built to show phosphorylated PKM2 in relation to total PKM2.
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were observed for PTC, however, these differences
were not significant.
Expression and phosphorylation of lactate
dehydrogenase A (y 10)
In comparison to PKM2, LDHA showed a more stable ex-
pression pattern within each group and between the differ-
ent histological subgroups (Figures 1, 7 and 8). The highest
expression of total LDHA was found in PTC. Furthermore,
the median expression of PTC was almost twofold higher
than in goiter. FTC also revealed significantly higher levels
of total LDHAas compared to goiter. UTC and FA demon-
strated a noticeable, but not significant increase in total
LDHA expression compared to goiter (Figure 7).
Analysis of phosphorylated LDHA revealed higher levels
of LDHA in each cancer subgroup (PTC, FTC and UTC)
in contrast to goiter. The median expression of total
LDHA was 54.9% in goiter, 75% in FA, 81.5% in FTC,
97.4% in PTC and 72.5% in UTC. Median Phospho-LDHA
levels were 25.1% in goiter, 43% in FA, 60.8% in FTC,Figure 9 mRNA expression of Lactate dehydrogenase A (LDHA). Expre
employment of Q-RT-PCR analysis. mRNA expression was measured in relat
expression of yWHAZ and GAPDH as normalizing markers. Differences are e
indicates a statistical significance.69.7% in PTC, 63.6% in UTC. PTC showed the highest me-
dian expression of total LDHA (97,4%) and the highest me-
dian level of Phospho-LDHA (69.7%). UTC revealed a
noticeable, however not significant up-regulation of LDHA
as compared to goiter. Phospho-LDHA / total LDHA ratio
showed significantly increased relative phosphorylation in
all cancer subgroups in comparison to goiter (Figure 8).
UTC and FTC showed significantly increased Phospho-
LDHA/total-LDHA ratio in comparison to follicular aden-
oma (FA) (Figure 8).
The correlation between the FGFR1 expression and
Phospho-LDHA levels was r 0.311 (p < 0.05) (data not
shown) and was even lower using a Phospho-LDHA/
LDHA ratio; r 0.226 (p < 0.05) (Figure 5). In histological
subgroups only FTC showed a significant correlation be-
tween FGFR1 and Phospho-LDHA/LDHA ratio at r
0.648 (p < 0.05) (data not shown). All other groups did
not show a significant correlation. However, in the group
of goiter tissue a correlation of r 0.444 (p = 0.057) (data
not shown) was found, being just outside of agreed stat-
istical significance.ssion of LDHA in goiter, FA, FTC, PTC and UTC was analysed by
ion to FTC133 as positive control and then normalized to the
xpressed as percent to positive control defined as 100%. *p < 0.05
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PCR analysis revealed significantly up-regulated expression
in UTC as compared to goiter. Also the differences be-
tween UTC and FTC tissues were significant. Expression
of LDHA in PTC showed an increased tendency as com-
pared to goiter or FA, however, these differences were not
significant (Figure 9 and 10).
Expression of fibroblast growth factor receptor 1 (FGFR1)
FGFR1 protein was expressed in all examined tissue sam-
ples. It was up-regulated significantly in PTC and UTC
compared to goiter or FA (Figure 11). FTC revealed lower
median expression of FGFR1 than in PTC and UTC, how-
ever being still noticeably higher than in FA or goiter.
Analysis of FGFR1 mRNA expression revealed a no-
ticeable increase in FA and all cancer subgroups com-
pared to goiter tissue. LDHA was found markedly higher
in FTC compared to FA or goiter without a statistical
difference observed. Only the differences between UTC
and goiter were statistically significant (Figure 9).Figure 10 mRNA expression of Fibroblast growth factor receptor 1 (F
analysed by employment of Q-RT-PCR analysis. mRNA expression was mea
the expression of yWHAZ and GAPDH as normalizing markers. Differences
indicates a statistical significance.Expression of phosphorylated PKM2 and LDHA under
FGFR1 inhibition
In order to investigate whether phosphorylation of PKM2
and LDHA is mediated in FGFR1-specific manner, FTC-
133 were treated with receptor tyrosine kinase inhibitors
Dovitinib and SU-5402. Dovitinib treatment resulted in
significant decrease of phosphorylation status at a concen-
tration of 100 nM after four hours of incubation for both
PKM2 and LDHA (Figure 12). No significant changes were
seen when administered at concentrations of 1 nM and 10
nM. SU-5402 administration led to a sigificant decrease of
PKM2 and LDHA phosphorylation at a concentration of
20 μM (Figure 12).
Discussion
In this study we demonstrated that total and phosphory-
lated PKM2 and LDHA proteins are significantly
up-regulated in thyroid cancer tissues as compared to
goiter. To our knowledge, in addition to previous PKM2
results in thyroid cancer [6], this is the first reportGFR1). Expression of FGFR1 in goiter, FA, FTC, PTC and UTC was
sured in relation to FTC133 as positive control and then normalized to
are expressed as percent to positive control defined as 100%. *p < 0.05
Figure 11 Evaluation of FGFR1 protein expression. Expression of FGFR1 in goiter, FA, FTC, PTC and UTC was analysed by employment of
western blot analysis and evaluated densitometrically with ImageJ software. Protein expression was measured in relation to FTC133 as positive
control and then normalized to the expression of ß-actin as normalizing marker. Differences are expressed in percent to positive control defined
as 100%. *p < 0.05 indicates a statistical significance.
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both proteins in thyroid cancer.
It is well known that in addition to the Warburg effect,
expression of PKM2 and LDHA in tumour tissues may be
regulated by Hypoxia inducible factor 1-alpha (HIF1a) and
c-Myc. Both oncogenes were also reported to be elevated
in thyroid malignancies [31-36]. With regards to our data,
we found that in thyroid carcinoma tissues PKM2 is
expressed more abundantly than LDHA. Based on these
observations we suggest that the Warburg effect is not the
only factor affecting PKM2 regulation in thyroid cancer,
especially in UTC. Furthermore, as reported in our study,
different expressional changes observed between PKM2
and LDHA may result from other than the enzymatic role
of PKM2 in gene transcription and proliferation [16,37,38].
Various other studies had previously demonstrated in-
creased levels of LDHA and PKM2 in tumour tissues
and their important role in proliferation and survival of
malignant cells [7,23,39]. In accordance with thesefindings we were able to show that thyroid carcinoma
samples revealed not only significantly elevated levels of
total PKM2 and LDHA compared to goiter or FA, but
this expressional increase correlated directly with phos-
phorylated forms of both proteins. Furthermore, our
data suggests that in patients with thyreoglobulin-
negative thyroid cancer, phosphorylated PKM2 and
LDHA may represent a more valuable diagnostic poten-
tial than total expressions of these proteins. Indeed, we
found that the FGFR1 expression correlated well with
phosphorylation status of both proteins. These results
suggest a possible, but not only FGFR1-mediated phos-
phorylation mechanism of PKM2 and LDHA in thyroid
carcinoma. However, increased phosphorylation of vari-
ous proteins and up-regulation of FGFR are known to
occur in cancer, being a possible confounder of our
conclusion.
We therefore conducted additional cell culture experi-
ments and were able to demonstrate that phosphorylation
Figure 12 Inhibition of FGFR and response in phosphorylation status of PKM2 and LDHA. Inhibiton experiments were performed with
Dovitinib and SU-5402, two inhibitors of Fibroblast growth factor receptor (FGFR). Phosphorylation status of PKM2 and LDHA was measured after
four hours and showed a significant decrease with Dovitinib 100nM and SU-5402 20 μM for both proteins. DMSO was used as positive control.
No significant downregulation of PKM2 and LDHA phosphorylation was detectable with 1nM and 10 nM of Dovitinib.
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Inhibition of FGFR1 in the thyroid cancer cell line FTC133
resulted in significantly decreased phosphorylation status
of both investigated enzymes. It is worth noting that tyro-
sine kinase inhibitors like Dovitinib or SU-5402 could be a
therapeutic option to target the Warburg effect in thyroid
cancer cells.
Discrimination between follicular adenoma (FA) and
FTC is often a challenge. Based on our data we noticed
a significantly increased relative phosphorylation of
PKM2 and LDHA (Figures 3 and 8) in FTC in compari-
son to FA. However, studies with early stage follicular
thyroid cancer are necessary to determine whether rela-
tive phosphorylation could be a tool to discriminate FTC
from FA.Conclusion
In summary, we demonstrated that increased levels of
total and phosphorylated forms of PKM2 and LDHA in
malignant tissues represent a novel expressional signa-
ture with diagnostic potential for thyroid cancer.Additional files
Additional file 1: Representative images of western blot performed
with total protein lysates obtained from thyroid tissues and antibodies
against PKM2 and total PKM (Pyruvate Kinase M2 and M1). 20 thyroid
samples were analyzed to show correlation between PKM2 and total
PKM. The Pearson correlation coefficient was 0.95, concluding that PKM2
is by far the predominant isoform in all examined thyroid tissue.
Additional file 2: Western blot images performed with total protein
lysates from three thyroid cancer cell lines: FTC133 (follicular
thyroid cancer cell line), 8505C (undifferentiated thyroid cancer cell
line) and B-CPAP (papillary thyroid cancer cell line). They were
stained with antibodies against PKM1, PKM2 total PKM and ß-actin and
showed stable expression of all examined proteins. Subsequently, FTC133
was chosen as positive control.
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